SCNX Stock — Scienture Holdings, Inc.

Scienture Holdings, Inc. (SCNX)

Updated October 16, 2026.

SCNX is a Stock. Total return is -100.0% over the past 17.7 years, 1253.6 points behind SPY at 1153.6%.

Scienture Holdings is a pharmaceutical company developing treatments for central nervous system and cardiovascular diseases, with a pipeline including oral losartan formulations, dihydroergotamine injection pens, thrombolytic agents, and non-opioid pain management therapies in various stages of clinical development. The company does not currently distribute to shareholders. This security may appeal to investors seeking exposure to early-stage pharmaceutical development, though it carries the risks inherent in clinical-stage drug companies with no established revenue base.

SCNX performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 17.7 years, 1253.6 points behind SPY at 1153.6%. Over the past year its total return — price change plus distributions reinvested — is -77.2%. Its deepest 1-year drawdown was 95.0%.

SCNX key facts

Asset type

Stock

Asset class

Equity

Inception date

01/26/2009

Distribution frequency

None

Last close

$3.36 (as of 2026-10-16)

Market cap

$5,519,018

Average volume

24145.0

Ex-dividend date

07/19/2024

Payment date

07/24/2024

Beta

4.084

Payout ratio

0.0%

Forward P/E

21.8341

EPS

$-52.75

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SCNX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 95.0%.

Who may consider SCNX — and who may not

It is a weaker fit for investors who need monthly cash flow (SCNX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SCNX

• All tickers starting with S

Tagged: Healthcare, Dividend.

Frequently asked questions